# Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)

> **NCT01983241** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Grifols Therapeutics LLC** · enrollment: 345 (actual)

## Conditions studied

- Pulmonary Emphysema in Alpha-1 PI Deficiency

## Interventions

- **BIOLOGICAL:** Alpha-1 MP
- **OTHER:** 0.9% Sodium Chloride for Injection, USP

## Key facts

- **NCT ID:** NCT01983241
- **Lead sponsor:** Grifols Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2013-11
- **Primary completion:** 2026-08
- **Final completion:** 2027-01
- **Target enrollment:** 345 (ACTUAL)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01983241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01983241, "Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01983241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*